share_log

Short Interest in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW) Drops By 46.0%

Defense World ·  Dec 30, 2022 05:11

Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 8,100 shares, a drop of 46.0% from the November 30th total of 15,000 shares. Based on an average daily volume of 15,600 shares, the days-to-cover ratio is presently 0.5 days.

Comera Life Sciences Price Performance

CMRAW stock opened at $0.05 on Friday. The stock's 50 day moving average is $0.05. Comera Life Sciences has a 52 week low of $0.03 and a 52 week high of $0.70.

Get Comera Life Sciences alerts:

Institutional Trading of Comera Life Sciences

A hedge fund recently bought a new stake in Comera Life Sciences stock. Warberg Asset Management LLC bought a new stake in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 202,000 shares of the company's stock, valued at approximately $29,000.

About Comera Life Sciences

(Get Rating)

Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.

Read More

  • Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRAW)
  • Should You Warm up to Generac Stock for the Winter?
  • Is Kintara Therapeutics A Hidden Gem?
  • 3 High-Yield Dividend Stocks to Hold for the Long Haul
  • Cal-Maine Posts Record Quarter, Remain CALM Income Investors
  • Tesla Stock: What the Bulls and the Bears Are Getting Wrong

Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment